452327AH2

• On August 17, 2026, Illumina completed a public offering of $300 million aggregate principal amount of 4.950% notes due September 19, 2029.
• The notes were issued under an indenture dated March 12, 2021, with U.S. Bank Trust Company as trustee, and an officer's certificate dated August 17, 2026.
• The offering was registered on Form S-3 (File No. 333-281921); interest is payable semi-annually at 4.950% per annum.
• The notes may be redeemed at Illumina's election, in whole or in part, under terms set forth in the notes.

8.01 Other Events · 9.01 Financial Statements and Exhibits

• The facility matures August 13, 2031, with three optional one-year extensions, and includes a $50M swingline sublimit and $75M letter of credit sublimit.
• Interest rates are variable based on SOFR or alternate base rate plus a margin tied to Illumina's debt rating.
• The agreement allows up to $500M in additional commitments or term loans, subject to lender consent.
• The prior credit agreement dated January 4, 2023 was terminated as of August 13, 2026; no borrowings were outstanding under the new facility at filing.

1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits

• The notes carry a 4.950% interest rate and mature in 2029; the offering is expected to close on August 17, 2026.
• Net proceeds, together with cash on hand, will be used to repay Illumina's 4.650% notes due September 9, 2026.
• The notes are offered under an existing Form S-3 registration statement (No. 333-281921) filed with the SEC on September 4, 2024.
• The underwriting agreement is filed as Exhibit 1.1 to this Form 8-K.

8.01 Other Events · 9.01 Financial Statements and Exhibits

• The settlement involves mutual releases and no payment by any party; the action will be dismissed with prejudice as to the plaintiffs only, without prejudice to other Illumina stockholders.
• The litigation challenged Illumina's $8 billion reacquisition of GRAIL, alleging breach of fiduciary duties by nine current and former directors.
• The court will hold a dismissal hearing on November 2, 2026, at 1:30 p.m. ET; a notice of pendency and proposed dismissal was filed as Exhibit 99.1.
• The dismissal does not affect three related derivative actions pending in the same court, and releases potential claims against Andrew Teno related to sharing confidential materials.

8.01 Other Events · 9.01 Financial Statements and Exhibits

• GAAP operating margin was 21.1% and non-GAAP operating margin was 22.5% for Q2 2026.
• GAAP diluted EPS was $1.35 and non-GAAP diluted EPS was $1.31 for Q2 2026.
• FY2026 guidance raised: total revenue now $4.60-$4.64 billion, non-GAAP diluted EPS $5.30-$5.40.
• Q2 2026 free cash flow was $162 million, down from $204 million in Q2 2025.
• Cash and cash equivalents plus short-term investments totaled $1.17 billion at quarter end.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Dr. Skovronsky is Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories.
• He will stand for election at Illumina's 2027 annual meeting of stockholders for a one-year term.
• He qualifies as an independent director under Nasdaq and SEC rules and has no reportable transactions with Illumina.
• He will participate in Illumina's non-employee director compensation programs as described in the April 9, 2026 proxy statement.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• Stockholders ratified Ernst & Young LLP as independent auditor for fiscal year ending January 3, 2027, with 133,174,094 votes for and 7,762,010 against.
• The advisory say-on-pay proposal for named executive officer compensation was approved with 121,746,792 votes for and 8,464,596 against.
• A quorum of 92.85% of outstanding shares (141,044,031 votes) was present, with 151,906,915 shares outstanding as of the March 26, 2026 record date.
• Final results were certified by the Inspector of Election on May 22, 2026.

5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• GAAP diluted EPS was $0.87; non-GAAP diluted EPS was $1.15.
• GAAP operating margin was 19.2%; non-GAAP operating margin was 21.9%.
• Board authorized a new $1.5 billion share repurchase program on April 28, 2026.
• FY2026 guidance raised: revenue $4.52-$4.62B, non-GAAP EPS $5.15-$5.30.

2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits